arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Ispire Technology Inc.

ISPR Health Care Medicinal Chemicals and Botanical Products
$1.54
Today
as of Sep 4, 16:50 ET
Last 30 days -3.75% Jul 28 → Sep 04
$1.34 $1.45 $1.56 $1.66 $1.77 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$1.54
High
$1.54
Low
$1.49
Volume
$5,965
Avg Vol
$81,657
Mkt Cap
$87M
P/E (TTM)
—
Beta
—
52w High
$3.87
52w Low
$1.01
Div Yield
—
Shares Out
$57M

Recent Press Releases & News last 60 days · 2 items

Aug 17 · 13:00 PR PR Newswire
Ispire Technology Inc. Appoints Steven Przybyla as President
Jul 22 · 11:08 MT Newswires
--BTIG Research Initiates Ispire Technology With Buy Rating, $3.50 Price Target

Overview

52-week range
$1.01
$3.87
19% of range
Avg surprise (last 3)
-298.0%
Avg reaction (last 2)
+7.3%
100% positive
Latest IV / EM
1454%
EM ±227.3% · $3 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.26$-0.20$-0.14$-0.07$-0.01 Actual $-0.01Actual $-0.05Actual $-0.02Actual $-0.07Actual $-0.11Actual $-0.10Actual $-0.14Actual $-0.19Est $-0.12Actual $-0.26Est $-0.14Actual $-0.12Actual $-0.17Est $-0.02 DecMarSepDecMarSepDecMar/2025Jun/2025DecMar/2026
Revenue vs Net Income Revenue Net income
$-11M$3M$17M$30M$44M Sep 24Dec 24Mar 25Sep 25Dec 25Mar 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Thu May 7, 2026Mar/2026 $-0.17 $-0.02 -750.0% +10.5% +10.1% earnings
Wed Dec 31, 2025Dec 2025 $-0.12 — — — — financials
Mon Sep 15, 2025Jun/2025 $-0.26 $-0.14 -85.7% — — earnings
Fri May 9, 2025Mar/2025 $-0.19 $-0.12 -58.3% — +4.5% earnings
Tue Dec 31, 2024Dec 2024 $-0.14 — — — — financials
Mon Sep 30, 2024Sep 2024 $-0.10 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.11 — — — — financials
Sun Dec 31, 2023Dec 2023 $-0.07 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.02 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.05 — — — — financials
Sat Dec 31, 2022Dec 2022 $-0.01 — — — — financials

Upcoming

DateFiscalTimeEPS EstLY EPSYoY %Δ
Mon Sep 21, 2026Jun/2026OTHER -$0.02-$0.26 +92.3%

Financials

Income statement (quarterly)

MetricMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
Revenue$19M$20M$30M—$26M$42M$39M—
Cost of revenue$17M$17M$25M—$21M$34M$32M—
Gross profit$2M$3M$5M—$5M$8M$8M—
Operating income$-9M$-7M$-3M—$-11M$-7M$-5M—
Net income$-10M$-7M$-3M—$-11M$-8M$-6M—
EPS (diluted)$-0.17$-0.12$-0.06—$-0.19$-0.14$-0.10—

Balance sheet (quarterly)

MetricMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
Cash & equivalents$18M$18M$23M$24M$24M$34M$38M$35M
Inventory$5M$5M$6M$7M$8M$8M$7M$6M
Total current assets$56M$64M$75M$73M$94M$112M$109M$103M
Total assets$76M$84M$96M$102M$116M$132M$129M$123M
Long-term debt————————
Total liabilities$92M$92M$98M$102M$101M$108M$98M$88M
Total equity$-16M$-8M$-2M$604,694$15M$24M$31M$34M

Implied volatility — last 90 days

279%1696%3113%4529%5946% Jun 07 — IV 1423% · EM ±197.1%Jun 08 — IV 1572% · EM ±207.6%Jun 09 — IV 1429% · EM ±179.0%Jun 10 — IV 1015% · EM ±119.9%Jun 11 — IV 1710% · EM ±189.0%Jun 12 — IV 1588% · EM ±162.5%Jun 15 — IV 1365% · EM ±98.7%Jun 16 — IV 1796% · EM ±106.1%Jun 17 — IV 4570% · EM ±190.9%Jun 19 — IV 280% · EM ±61.9%Jun 22 — IV 282% · EM ±58.8%Jun 23 — IV 461% · EM ±94.4%Jun 24 — IV 453% · EM ±90.7%Jun 25 — IV 362% · EM ±71.0%Jun 26 — IV 714% · EM ±136.7%Jun 29 — IV 1073% · EM ±190.1%Jun 30 — IV 1970% · EM ±339.3%Jul 01 — IV 2363% · EM ±394.7%Jul 02 — IV 2136% · EM ±345.5%Jul 03 — IV 2211% · EM ±345.5%Jul 06 — IV 2740% · EM ±379.5%Jul 07 — IV 3098% · EM ±409.1%Jul 08 — IV 1516% · EM ±189.9%Jul 09 — IV 1831% · EM ±216.3%Jul 10 — IV 2082% · EM ±230.1%Jul 13 — IV 1706% · EM ±142.5%Jul 14 — IV 1382% · EM ±100.0%Jul 15 — IV 2792% · EM ±164.9%Jul 16 — IV 3694% · EM ±154.3%Jul 20 — IV 443% · EM ±104.5%Jul 21 — IV 911% · EM ±211.8%Jul 22 — IV 553% · EM ±126.5%Jul 23 — IV 326% · EM ±73.2%Jul 24 — IV 861% · EM ±190.3%Jul 27 — IV 680% · EM ±142.0%Jul 28 — IV 657% · EM ±134.4%Jul 29 — IV 1232% · EM ±246.7%Jul 30 — IV 869% · EM ±170.1%Jul 31 — IV 1081% · EM ±206.9%Aug 03 — IV 819% · EM ±145.1%Aug 04 — IV 1048% · EM ±180.4%Aug 05 — IV 847% · EM ±141.5%Aug 06 — IV 596% · EM ±96.4%Aug 07 — IV 617% · EM ±96.5%Aug 10 — IV 752% · EM ±104.2%Aug 11 — IV 892% · EM ±117.8%Aug 12 — IV 854% · EM ±106.9%Aug 13 — IV 1038% · EM ±122.6%Aug 14 — IV 1255% · EM ±138.7%Aug 17 — IV 1563% · EM ±130.6%Aug 18 — IV 1930% · EM ±139.6%Aug 19 — IV 4176% · EM ±246.7%Aug 20 — IV 5946% · EM ±248.3%Aug 24 — IV 874% · EM ±182.5%Aug 25 — IV 1214% · EM ±248.3%Aug 26 — IV 934% · EM ±187.1%Aug 27 — IV 1402% · EM ±274.6%Aug 28 — IV 957% · EM ±183.1%Aug 31 — IV 806% · EM ±142.9%Sep 01 — IV 801% · EM ±137.9%Sep 02 — IV 946% · EM ±158.1%Sep 03 — IV 1119% · EM ±180.9%Sep 04 — IV 1454% · EM ±227.3%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in